Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer
| Status: |
History |
| Expected date of issue: |
April 2011 |
| Referral date: |
November 2008 |
| Wave: |
19 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Peter Littlejohns
|
| Technical Lead: |
Helen Tucker
|
| Communications manager: |
Alice Law
|
| Project manager: |
Kate Moore
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
19 January 2010 |
| 1st appraisal committee meeting: |
27 April 2010 |
| 2nd appraisal committee meeting |
27 October 2010 |
| 3rd appraisal committee meeting: |
25 January 2011 |
Consultees and commentators
|
| Consultees |
Commentators (no right to submit or appeal) |
|
Manufacturers/sponsors
Patient/carer groups
- Macmillan Cancer Support
- Roy Castle Lung Cancer Foundation
Professional groups
- British Thoracic Society
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- Royal College of Nursing
- Royal College of Physicians’ Intercollegiate Lung Cancer Group
- United Kingdom Oncology Nursing Society
Others
- Cornwall and the Isles of Scilly PCT
- Department of Health
- Dudley PCT
- Welsh Assembly Government
|
General
- NHS Quality Improvement Scotland
Comparator manufacturers
- Eli Lilly & Co. (pemetrexed)
Relevant research groups
- British Thoracic Oncology Group
Evidence Review Group
- Liverpool Reviews and Implementation Group (LRIG)
- National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
- National Collaborating Centre for Cancer
Associated Public Health Groups
|
|
Project history
| Date |
Update |
| 21 July 2010 |
The discussion of erlotinib monotherapy for the maintenance treatment of non small cell lung cancer at the Appraisal Committee meeting, planned for 27 July 2010, will be postponed. The manufacturer of erlotinib, Roche, asked for the opportunity to submit an extensive amount of new evidence that will require additional time to be reviewed by the Evidence Review Group. This new evidence is related to receipt of the final marketing authorisation for erlotinib in this indication and the publication of related NICE guidance.
A new committee date will announced in due course. |
| 28 May 2010 |
The Appraisal Committee met to discuss the STA of erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer on 27 April 2010.
The manufacturer included a proposed Patient Access Scheme (PAS) in their evidence submission. The Department of Health advised that it would be reasonable for the Appraisal Committee to consider the proposed PAS at that meeting, however it was not able to confirm the final status of the PAS. NICE can only issue the ACD once formal ministerial sign off has been received. Therefore the ACD cannot yet be issued and erlotinib will no longer be discussed by the Appraisal Committee on 23 June 2010. We will let you know as soon as possible when we can proceed to ACD consultation and apologise that we cannot provide more clarity about the future timelines for this appraisal. |
| 15 May 2009 |
The above appraisal has been rescheduled to align with latest regulatory expectations. We expect a new submission date in November 2009. |
|
Key documents
 |
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): EIA form
|
29 June 2011 |
 |
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal
|
07 April 2011 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final appraisal determination
|
10 March 2011 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appraisal consultation 2
|
24 November 2010 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appraisal consultation
|
16 June 2010 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee and commentator comments on the provisional matrix
|
17 November 2009 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee and commentator comments on the draft scope
|
17 November 2009 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final scope
|
17 November 2009 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): draft scope
|
06 October 2009 |
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): provisional matrix
|
06 October 2009 |
|
This page was last updated: 29 June 2011
